Curative effects of interferon-α and HLA-DRB1 -DQA1 and -DQB1 alleles in chronic viral hepatitis B

World Journal of Gastroenterology

Volumn 10, Issue 14, 2004, Pages 2116-2118

  Zang, Guo Qing ^a   Xi, Min ^a   Feng, Ming Liang ^b   Ji, Yun ^b   Yu, Yong Sheng ^a   Tang, Zheng Hao ^a  

^a Otolaryngology Institute of Shanghai   (China)

^b Shanghai Blood Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; ANTIVIRUS AGENT; HLA ANTIGEN; HLA DQ ANTIGEN; HLA-DRB1 ANTIGEN;

ADULT; ALLELE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CHINA; CHRONIC HEPATITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; HEPATITIS B; HUMAN; IMMUNOFLUORESCENCE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRUS HEPATITIS; GENETICS;

ADULT; ALLELES; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B, CHRONIC; HLA ANTIGENS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; INTERFERON-ALPHA; MALE; TREATMENT OUTCOME;

EID: 4043062021     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i14.2116     Document Type: Article

References (24)

1. World Health Organization, 1998. Hepatitis Bfact Sheet WHO/204. http://www.who.int/inf-fs/en/fact203.html
2. van Hattum J, Schreuder GM, Schalm SW. HLA antigens in patients with various courses after hepatitis B virus infection. Hepatology 1987; 7: 11-14
3. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466
4. Miyaguchi S, Saito H, Ebinuma H, Morizane T, Ishii H. Possible association between HLA antigens and the response to interferon in Japanese patients with chronic hepatitis C. Tissue Antigens 1997; 49: 605-611
5. Cotrina M, Buti M, Jardi R, Rodriguez-Frias F, Campins M, Esteban R, Guardia J. Study of HLA-II antigens in chronic hepatitis C and B and in acute hepatitis B. Gastroenterol Hepatol 1997; 20: 115-118
6. Sobao Y, Sugi K, Tomiyama H, Saito S, Fujiyama S, Morimoto M, Hasuike S, Tsubouchi H, Tanaka K, Takiguch M. Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*2402, the most common HLA class I allele in East Asia. J Hepatol 2001; 34: 922-929
7. Thimme R, Chang KM, Pemberton J, Sette A, Chisari FV. Degenerate immunogenicity of an HLA-A2-restricted hepatitis B virus nucleocapsid cytotoxic T-lymphocyte epitope that is also presented by HLA-B51. J Virol 2001; 75: 3984-3987
8. Shen JJ, Ji Y, Guan XL, Huang RJ, Sun YP. The association of HLA-DRB1*10 with chronic hepatitis B in Chinese patients. Zhonghua Weishengwuxue He Mianyixue Zazhi 1999; 19: 58-59
9. China physic association infectious disease & verminosis association liver disease sub-association viral hepatitis prevention & cure project. Zhonghua Ganzangbing Zazhi 2000; 8: 324-329
10. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers(PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-235
11. Chen WN, Oon CJ. Mutation "hot spot" in HLA class I restricted T cell epitope on hepatitis B surface antigen in chronic carriers and hepatocellular carcinoma. Biochem Biophys Res Commun 1999; 262: 757-761
12. McDermott AB, Cohen SB, Zuckerman JN, Madrigal JA. Human leukocyte antigens influence the immune response to a pre-S/S hepatitis B vaccine. Vaccine 1999; 17: 330-339
13. McDermott AB, Madrigal JA, Sabin CA, Zuckerman JN, Cohen SB. The influence of host factors and immunogenetics on lymphocyte responses to hepagene vaccination. Vaccine 1999; 17: 1329-1337
14. 2 immune response and chronic hepatitis B virus infection. Shijie Huaren Xiaohua Zazhi 1999; 7: 513-515
15. Jiang YG, Wang YM, Liu TH, Liu J. Association between HLA class II gene and susceptibility or resistance to chronic hepatitis B. World J Gastroenterol 2003; 9: 2221-2225
16. Diepolder HM, Jung MC, Keller E, Schrant W, Gerlach JT, Gruner N, Zachoval R, Hoffmann RM, Schirren CA, Scholz S, Pape GR. A vigorous virus-specific CD4+ T cell response may contribute to the association of HLA-DR13 with viral clearance in hepatitis B. Clin Exp Immunol 1998; 113: 244-251
17. Thursz MR, Kwiatkowski D, Allsopp CE, Greenwood BM, Thomas HC, Hill AV. Association between an MHC class II allele and clearance of hepatitis B virus in the gambia. New Engl J Med 1995; 332: 1065-1069
18. Hohler T, Gerken G, Notghi A, Lubjuhn R, Taheri H, Protzer U, Lohr HF, Schneider PM, Meyer zum Buschenfelde KH, Rittner C. HLA-DRB1*1301 and *1302 Protect against chronic hepatitis B. J Hepatol 1997; 26: 503-507
19. Bhimma R, Hammond MG, Coovadia HM, AdhiKari M, Connolly CA. HLA class I and II in black children with hepatitis B virus-associated membranous nephropathy. Kidney Int 2002; 61: 1510-1515
20. Jiang YG, Wang YM. Association between HLA-DRB1*1001 and severity of chronic hepatitis B. Zhonghua Ganzangbing Zazhi 2003; 11: 256
21. Tibbs C, Donaldson P, Underhill J, Thomson L, Manabe K, Williams R. Evidence that the HLA DQA1 *03 allele confers protection from chronic HCV-infection in northern european caucasoids. Hepatology 1996; 24: 1342-1345
22. Lee M, Lee SK, Son M, Cho SW, Park S, Kim HI. Expression of Th1 and Th2 type cytokines responding to HBsAg and HBxAg in chronic hepatitis B patient. J Korean Med Sci 1999; 14: 175-181
23. Qian Y, Zhang L, Hou JL. Association between non-response to interferon and HLA-DRB1*07 genes in chronic hepatitis Bindividuals. Mianyixue Zazhi 2002; 18: 371-374
24. Dincer D, Besisik F, Oguz F, Sever MS, Kaymakoglu S, Cakaloglu Y, Demir K, Turkoglu S, Carin M, Okten A. Genes of major histocompatibility complex class II influence chronic C hepatitis treatment with interferon in hemodialysis patients. Int J Artiforgans 2001; 24: 212-214